Congestive/JJ Heart/NN Failure/NN ,/, or/CC CHF/NNP ,/, is/VBZ a/DT serious/JJ medical/JJ condition/NN that/WDT can/MD result/VB in/IN fluid/JJ buildup/NN in/IN the/DT body/NN as/IN a/DT result/NN of/IN a/DT weak/JJ heart/NN ./.
When/WRB the/DT heart/NN ca/MD n't/RB pump/VB enough/JJ blood/NN to/TO efficiently/RB deliver/VB nutrients/NNS and/CC oxygen/NN to/IN the/DT body/NN ,/, kidney/NN function/NN may/MD be/VB impaired/VBN ,/, resulting/VBG in/IN fluid/NN retention/NN ./.
CHF/NN patients/NNS require/VBP a/DT broad/JJ drug/NN regimen/NN to/TO maintain/VB the/DT delicate/JJ system/NN balance/NN ,/, particularly/RB between/IN their/PRP$ heart/NN and/CC kidneys/NNS ./.
These/DT drugs/NNS include/VBP ACE/NN inhibitors/NNS and/CC Beta/NN Blockers/NNS to/TO control/VB blood/NN pressure/NN ,/, anticoagulants/NNS to/TO prevent/VB blood/NN clots/NNS ,/, and/CC diuretics/NNS to/TO reduce/VB fluid/NN overload/NN ./.
Many/JJ of/IN these/DT drugs/NNS may/MD interact/VB ,/, and/CC potential/JJ effects/NNS of/IN these/DT interactions/NNS must/MD be/VB weighed/VBN against/IN their/PRP$ benefits/NNS ./.
For/IN this/DT project/NN ,/, we/PRP consider/VBP a/DT set/NN of/IN 44/CD drugs/NNS identified/VBN as/IN specifically/RB relevant/JJ for/IN treating/VBG CHF/NN by/IN pediatric/JJ cardiologists/NNS at/IN Lucile/NNP Packard/NNP Children/NNP 's/POS Hospital/NNP ./.
This/DT list/NN was/VBD generated/VBN as/IN part/NN of/IN our/PRP$ current/JJ work/NN at/IN the/DT LPCH/NNP Heart/NNP Center/NNP ./.
The/DT goal/NN of/IN this/DT project/NN is/VBZ to/TO identify/VB and/CC evaluate/VB potentially/RB harmful/JJ drug/NN -/HYPH drug/NN interactions/NNS (/-LRB- DDIs/NNS )/-RRB- within/IN pediatric/JJ patients/NNS with/IN Congestive/JJ Heart/NN Failure/NN ./.
This/DT identification/NN will/MD be/VB done/VBN autonomously/RB ,/, so/IN that/IN it/PRP may/MD continuously/RB update/VB by/IN evaluating/VBG newly/RB published/VBN literature/NN ./.
